国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2015年
1期
32-36
,共5页
乳腺肿瘤%基因,BRCA1%Meta分析
乳腺腫瘤%基因,BRCA1%Meta分析
유선종류%기인,BRCA1%Meta분석
Breast neoplasms%Genes,BRCA1%Meta-analysis
目的 对三阴性乳腺癌患者发生BRCA1基因突变风险进行系统综合评价.方法 从PubMed、中国期刊全文数据库、万方、维普、中国生物医学文献数据库中检索相关文献,用比值比(OR)评价三阴性乳腺癌患者发生BRCA1基因突变的风险,用Rev-Man 5.2软件进行Meta分析.结果 共纳入23篇文献,其中三阴性乳腺癌患者1 104例,非三阴性乳腺癌患者4 245例.合并OR及95％ CI为7.67(6.24 ～ 9.42),差异有统计学意义(Z=19.38,P＜0.000 01).在有关人种的亚组分析中,亚洲人合并OR及95％ CI为6.67(4.98 ～8.95),高加索人合并OR及95％ CI为8.83(6.61～11.80),差异有统计学意义(Z=14.74,P＜0.000 01).结论 BRCA1基因在三阴性乳腺癌患者中的突变风险是非三阴性乳腺癌患者的7.67倍.需要大样本的随机对照试验进一步证实,从而使得BRCA1基因突变检测可以常规应用于临床三阴性乳癌患者中.
目的 對三陰性乳腺癌患者髮生BRCA1基因突變風險進行繫統綜閤評價.方法 從PubMed、中國期刊全文數據庫、萬方、維普、中國生物醫學文獻數據庫中檢索相關文獻,用比值比(OR)評價三陰性乳腺癌患者髮生BRCA1基因突變的風險,用Rev-Man 5.2軟件進行Meta分析.結果 共納入23篇文獻,其中三陰性乳腺癌患者1 104例,非三陰性乳腺癌患者4 245例.閤併OR及95％ CI為7.67(6.24 ～ 9.42),差異有統計學意義(Z=19.38,P＜0.000 01).在有關人種的亞組分析中,亞洲人閤併OR及95％ CI為6.67(4.98 ～8.95),高加索人閤併OR及95％ CI為8.83(6.61～11.80),差異有統計學意義(Z=14.74,P＜0.000 01).結論 BRCA1基因在三陰性乳腺癌患者中的突變風險是非三陰性乳腺癌患者的7.67倍.需要大樣本的隨機對照試驗進一步證實,從而使得BRCA1基因突變檢測可以常規應用于臨床三陰性乳癌患者中.
목적 대삼음성유선암환자발생BRCA1기인돌변풍험진행계통종합평개.방법 종PubMed、중국기간전문수거고、만방、유보、중국생물의학문헌수거고중검색상관문헌,용비치비(OR)평개삼음성유선암환자발생BRCA1기인돌변적풍험,용Rev-Man 5.2연건진행Meta분석.결과 공납입23편문헌,기중삼음성유선암환자1 104례,비삼음성유선암환자4 245례.합병OR급95％ CI위7.67(6.24 ～ 9.42),차이유통계학의의(Z=19.38,P＜0.000 01).재유관인충적아조분석중,아주인합병OR급95％ CI위6.67(4.98 ～8.95),고가색인합병OR급95％ CI위8.83(6.61～11.80),차이유통계학의의(Z=14.74,P＜0.000 01).결론 BRCA1기인재삼음성유선암환자중적돌변풍험시비삼음성유선암환자적7.67배.수요대양본적수궤대조시험진일보증실,종이사득BRCA1기인돌변검측가이상규응용우림상삼음성유암환자중.
Objective To systematically evaluate the risk of BRCA1 mutation in patients with triplenegative breast cancer (TNBC).Methods Articles about the association between the TNBC and BRCA1 mutation were retrieved from database,such as PubMed,CNKI,Wanfang,VIP and CBM databases.The odds ratio (OR) was used to evaluate the risk of BRCA1 mutation in TNBC compared with non-TNBC.Rev Man 5.2 software was applied to perform the Meta-analysis.Results A total of 23 articles were eligible for the Meta-analysis,including 1 104 patients with TNBC and 4 245 patients with non-TNBC.The pooled OR was 7.67 and 95％ CI(6.24,9.42),and the difference was statistically significant (Z =19.38,P ＜ 0.000 01).In the subgroup analysis about the race,the pooled OR for Asian was 6.67 and 95％ CI (4.98,8.95).The pooled OR for Caucasian was 8.83 and 95％ CI (6.61,11.80).There was statistically significant difference in the pooled OR between the Asian and the Caucasian (Z =14.74,P ＜ 0.000 01).Conclusion The patients with TNBC are 7.67 times more likely to have BRCA1 mutation compared with non-TNBC phenotype.Largesample randomized controlled trials are warranted to demonstrate the detection of BRCA1 mutation can be a conven-tional application in clinical for the patients with TNBC.
